HRP20120989T1 - Peptidi koji se vežu za receptor eritropoetina - Google Patents
Peptidi koji se vežu za receptor eritropoetina Download PDFInfo
- Publication number
- HRP20120989T1 HRP20120989T1 HRP20120989TT HRP20120989T HRP20120989T1 HR P20120989 T1 HRP20120989 T1 HR P20120989T1 HR P20120989T T HRP20120989T T HR P20120989TT HR P20120989 T HRP20120989 T HR P20120989T HR P20120989 T1 HRP20120989 T1 HR P20120989T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- peg
- peptide dimer
- daltons
- molecular weight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Claims (37)
1. Peptid s 17 do 40 aminokiselinskih ostataka u dužini koji sadrži sekvencu aminokiselina:
LYACHX0GPITX1VCQPLR (SEQ ID NO: 1),
gdje je X0 ostatak izabran između metionina (M) i homoserin metiletera (Hsm), i X1 je ostatak izabran između triptofana (W), 1-naftilalanina (1-nal), i 2-naftilalanina (2-nal),
gdje se taj peptid veže za i aktivira receptor eritropoetina (EPO-R).
2. Peptid prema zahtjevu 1, gdje je N-kraj tog peptida acetiliran.
3. Peptid prema zahtjevu 1 ili zahtjevu 2, taj peptid sadrži sekvencu aminokiselina izabranu između:
[image]
[image]
4. Peptid prema bilo kojem od zahtjeva 1 do 3, gdje je peptid monomer.
5. Peptid prema bilo kojem od zahtjeva 1 do 4, koji dalje sadrži jedan ili više polimera topljivih u vodi koji su kovalentno povezani s peptidom.
6. Peptid prema zahtjevu 5, gdje je polimer topljiv u vodi polietilenglikol (PEG).
7. Peptid prema zahtjevu 6, gdje taj PEG sarži linearnu nerazgranatu molekulu s molekularnom težinom od 500 do 60,000 Daltona.
8. Peptid prema zahtjevu 7, gdje PEG ima molekularnu težinu manju od 20,000 Daltona.
9. Peptid prema zahtjevu 7, gdje PEG ima molekularnu težinu od 20,000 do 60,000 Daltona.
10. Peptid prema bilo kojem od zahtjeva 6-7 i 9, gdje PEG ima molekularnu težinu od 20,000 do 40,000 Daltona.
11. Peptid prema zahtjevu 7, gdje su dvije PEG jedinke kovalentno vezane za peptid, svaki od tih PEG sadrži linearnu nerazgranatu molekulu.
12. Peptid prema zahtjevu 11, gdje svaki PEG ima molekularnu težinu od 20,000d 30,000 Daltona.
13. Peptidni dimer koji sadrži dva monomera, oba ta monomera su peptid prema bilo kojem od zahtjeva 1 do 3 i 5 do 12.
14. Peptidni dimer prema zahtjevu 13, gdje je peptid homodimer.
15. Peptidni dimer prema zahtjevu 13, sadrži:
(a) prvi peptidni lanac;
(b) drugi peptidni lanac; i
(c) povezujuću jedinku koja spaja prvi i drugi peptidni lanac,
gdje su oba, i prvi peptidni lanac i drugi peptidni lanac, peptidi prema zahtjevu 1.
16. Peptidni dimer prema zahtjevu 15, gdje barem jedan od prvog peptidnog lanca i drugog peptidnog lanca sadrži sekvencu aminokiselina izabranu između:
[image]
[image]
17. Peptidni dimer prema zahtjevu 15, gdje povezujuća jedinka obuhvaća formulu:
-NH-R3-NH-
gdje R3 je C1-6 alkilen.
18. Peptidni dimer prema zahtjevu 17, gdje je povezujuća jedinka ostatak lizina.
19. Peptidni dimer prema zahtjevu 15, gdje povezujuća jedinka obuhvaća formulu:
-CO-(CH2)n-X-(CH2)m-CO-
gdje je n cijeli broj od 0 do je cijeli broj od 1 do 10, X se izabire između O, S, N(CH2)pNR1, NCO(CH2)pNR1, i CHNR1, R1 se izabire između H, Boc, i Cbz, i p je cijeli broj od 1 do 10.
20. Peptidni dimer prema zahtjevu 19, gdje su n i m svaki 1, X je NCO(CH2)pNR1, p je 2, i R1 je H.
21. Peptidni dimer prema zahtjevu 15, dalje sadrži u vodi topljivi polimer.
22. Peptidni dimer prema zahtjevu 21, gdje je u vodi topljivi polimer kovalentno vezan za povezujuću jedinku.
23. Peptidni dimer prema zahtjevu 15, dalje sadrži razmaknicu.
24. Peptidni dimer prema zahtjevu 23, gdje razmaknica obuhvaća formulu:
-NH-(CH2)α-[O-(CH2)β]γ-Oδ-(CH2)ε-Y-
gdje α, β, i ε su cijeli brojevi čije su vrijednosti nezavisno izabrane između 1 do 6, δ je 0 ili 1, γ je cijeli broj izabran između 0 do 10, i Y je izabran između NH ili CO, uz uvjet da je 2 kada je γ veći od 1.
25. Peptidni dimer prema zahtjevu 24 gdje je svaki od α, β, i ε jednak 2, svaki od γ i δ je 1, i Y je NH.
26. Peptidni dimer prema zahtjevu 23, dalje sadrži jedan ili više u vodi topljivih polimera.
27. Peptidni dimer prema zahtjevu 26, gdje je u vodi topljivi polimer kovalentno vezan za razmaknicu.
28. Peptidni dimer prema zahtjevu 21 ili 26, gdje je u vodi topljivi polimer polietilenglikol (PEG).
29. Peptidni dimer prema zahtjevu 28, gdje PEG je linearni nerazgranati PEG s molekularnom težinom od 500 do 60,000 Daltona.
30. Peptidni dimer prema zahtjevu 28 ili 29, gdje PEG ima molekularnu težinu od 500 do manje od 20,000 Daltona.
31. Peptidni dimer prema zahtjevu 28 ili 29, gdje PEG ima molekularnu težinu od 20,000 do 60,000 Daltona.
32. Peptidni dimer prema zahtjevu 28, 29 ili 31, gdje PEG ima molekularnu težinu od 20,000 do 40,000 Daltona.
33. Peptidni dimer prema zahtjevu 28, gdje su dvije PEG jedinke kovalentno vezane za peptid, svaki od tih PEG sadrži linearnu nerazgranatu molekulu.
34. Peptidni dimer prema zahtjevu 33, gdje svaki PEG ima molekularnu težinu od 20,000 do 30,000 Daltona.
35. Peptid ili peptidni dimer prema bilo kojem od zahtjeva 1 do 34 za uporabu u liječenju poremećaja naznačenog manjkom eritropoetina ili niskom ili manjkavom populacijom crvenih krvnih stanica.
36. Peptid ili peptidni dimer za uporabu prema zahtjevu 35, gdje se poremećaj izabire iz skupine koja obuhvaća: zadnji stupanj zatajenja bubrega ili dijaliza; anemija povezana s AIDS-om, autoimunom bolesti ili malignitetom; betatalasemija; cistična fibroza; rana anemija preuranjene zrelosti; anemija povezana s kroničnom inflamatornom bolesti; ozljeda leđne moždine; akutni gubitak krvi; starenje; i stanja neoplastične bolesti praćena abnormalnom eritropoezom.
37. Farmaceutski oblik koji sadrži:
(i) peptid ili peptidni dimer prema bilo kojem od zahtjeva 1 do 34; i
(ii) farmaceutski prihvatljivi nosač.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47024503P | 2003-05-12 | 2003-05-12 | |
| PCT/US2004/014886 WO2004101611A2 (en) | 2003-05-12 | 2004-05-12 | Peptides that bind to the erythropoietin receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120989T1 true HRP20120989T1 (hr) | 2013-01-31 |
Family
ID=33452385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120989TT HRP20120989T1 (hr) | 2003-05-12 | 2004-05-12 | Peptidi koji se vežu za receptor eritropoetina |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US7528104B2 (hr) |
| EP (1) | EP1625156B1 (hr) |
| JP (1) | JP4949844B2 (hr) |
| KR (2) | KR20120094001A (hr) |
| CN (1) | CN1823088B (hr) |
| AU (1) | AU2004238868B2 (hr) |
| BR (1) | BRPI0411172A (hr) |
| CA (1) | CA2525497A1 (hr) |
| DK (1) | DK1625156T3 (hr) |
| EA (1) | EA010099B1 (hr) |
| ES (1) | ES2395413T3 (hr) |
| HR (1) | HRP20120989T1 (hr) |
| IL (1) | IL198844A0 (hr) |
| IS (1) | IS8167A (hr) |
| MX (1) | MXPA05012313A (hr) |
| NO (1) | NO20055847L (hr) |
| NZ (1) | NZ543935A (hr) |
| PL (1) | PL1625156T3 (hr) |
| PT (1) | PT1625156E (hr) |
| SI (1) | SI1625156T1 (hr) |
| WO (1) | WO2004101611A2 (hr) |
| ZA (1) | ZA200509971B (hr) |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7259146B2 (en) | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| BRPI0411172A (pt) | 2003-05-12 | 2006-07-18 | Affymax Inc | peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica |
| CA2525568C (en) | 2003-05-12 | 2017-07-25 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| EA010015B1 (ru) * | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов |
| CA2525464A1 (en) * | 2003-05-12 | 2004-11-25 | Qun Yin | Novel poly(ethylene glycol) modified compounds and uses thereof |
| US20060228331A1 (en) * | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| ES2428358T3 (es) * | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
| US8034326B2 (en) | 2005-04-18 | 2011-10-11 | Novo Nordisk A/S | IL-21 variants |
| US8324159B2 (en) | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US20090042790A1 (en) * | 2005-06-13 | 2009-02-12 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
| EP3669894A3 (en) | 2006-06-30 | 2020-08-26 | Syntab Therapeutics GmbH | Novel multifunctional compounds for pharmaceutical purposes |
| US8475784B2 (en) | 2006-10-26 | 2013-07-02 | Novo Nordisk A/S | IL-21 variants |
| DK2076290T3 (en) | 2006-10-27 | 2017-01-23 | Sunnybrook Health Sciences Center | MULTIMERIC TIE 2 AGONISTS AND APPLICATIONS THEREOF IN STIMULATING ANGIOGENESIS |
| EP2109620B1 (en) * | 2006-12-21 | 2012-08-22 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| US8106154B2 (en) | 2007-01-31 | 2012-01-31 | Affymax, Inc. | Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules |
| WO2009002947A2 (en) * | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| EP2018835B1 (de) | 2007-07-09 | 2014-03-05 | Augustinus Bader | Wirkstoff abgebendes Pflaster |
| EP2195002A4 (en) * | 2007-08-22 | 2011-09-07 | Affymax Inc | ERYTHROPOETIN RECEPTOR PEPTIDE FORMULATIONS AND USES |
| US8383114B2 (en) | 2007-09-27 | 2013-02-26 | Amgen Inc. | Pharmaceutical formulations |
| ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
| CN101456911A (zh) * | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
| JP2011513206A (ja) * | 2008-01-04 | 2011-04-28 | バイオトロフィックス，インコーポレーテッド | 増強された非共有的受容体結合のための方法および組成物 |
| EP2247618B1 (en) | 2008-01-25 | 2014-06-11 | Amgen, Inc | Ferroportin antibodies and methods of use |
| JP2009191056A (ja) * | 2008-02-15 | 2009-08-27 | Affymax Inc | 合成ペプチドをベースとするｅｐｏレセプターアゴニストを用いた抗エリスロポエチン抗体に媒介された障害の治療 |
| EP2294087B1 (en) | 2008-05-01 | 2014-05-14 | Amgen, Inc. | Anti-hepcidin antibodies and methods of use |
| CA3019967A1 (en) | 2008-11-13 | 2010-05-20 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation of bmp-6 |
| WO2011012306A2 (en) | 2009-07-30 | 2011-02-03 | Aplagen Gmbh | Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis |
| WO2011050333A1 (en) | 2009-10-23 | 2011-04-28 | Amgen Inc. | Vial adapter and system |
| EA032537B1 (ru) | 2010-06-07 | 2019-06-28 | Эмджен Инк. | Способ работы устройства для доставки лекарственного средства |
| EP2590666B1 (en) | 2010-07-06 | 2017-04-26 | Augustinus Bader | Topical application of erythropoietin for use in the treatment of injuries of the cornea |
| AU2012236573B2 (en) | 2011-03-31 | 2016-06-02 | Amgen Inc. | Vial adapter and system |
| AU2012245231B2 (en) | 2011-04-20 | 2016-10-13 | Amgen Inc. | Autoinjector apparatus |
| DK2574357T3 (da) * | 2011-09-28 | 2014-02-03 | Q Med Ab | Elektronisk injektor |
| CN103930142B (zh) | 2011-10-14 | 2016-12-14 | 安姆根有限公司 | 注射器和装配方法 |
| CN103421094A (zh) * | 2012-05-24 | 2013-12-04 | 上海医药工业研究院 | 一种具有epo类似活性的多肽化合物 |
| CN103450348B (zh) * | 2012-05-29 | 2016-03-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种促红细胞生成素模拟肽、其制备方法和用途 |
| EP2922590B1 (en) | 2012-11-21 | 2020-02-05 | Amgen Inc. | Drug delivery device |
| CA2904725C (en) | 2013-03-15 | 2022-04-12 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| CA2904661C (en) | 2013-03-15 | 2022-03-15 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| ES2695166T3 (es) | 2013-03-15 | 2019-01-02 | Intrinsic Lifesciences Llc | Anticuerpos antihepcidina y usos de los mismos |
| BR112015022042B1 (pt) | 2013-03-15 | 2023-01-10 | Amgen Inc | Injetor para injetar um produto terapêutico |
| CA2897825C (en) | 2013-03-22 | 2022-05-24 | Scott R. Gibson | Injector and method of assembly |
| CA2920894C (en) | 2013-10-24 | 2023-03-14 | Amgen Inc. | Injector and method of assembly |
| MX2016005315A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Sistema de administracion de farmacos con control sensible a la temperatura. |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| CA2945026C (en) | 2014-05-07 | 2023-10-10 | Amgen Inc. | Autoinjector with shock reducing elements |
| IL297356A (en) | 2014-06-03 | 2022-12-01 | Amgen Inc | Controllable drug delivery system and method of use |
| WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| WO2016061220A2 (en) | 2014-10-14 | 2016-04-21 | Amgen Inc. | Drug injection device with visual and audio indicators |
| US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
| JP2017538512A (ja) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置 |
| WO2016133947A1 (en) | 2015-02-17 | 2016-08-25 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| EP3261690B1 (en) | 2015-02-27 | 2021-12-15 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| CN106554394B (zh) * | 2015-09-30 | 2019-08-16 | 天津药物研究院有限公司 | 一种促红细胞生成素模拟肽及其制备方法和应用 |
| CN106608911B (zh) * | 2015-10-22 | 2020-01-07 | 天津药物研究院有限公司 | 一种二硫键修饰的epo拟肽衍生物及其制备方法和应用 |
| CN106608913B (zh) * | 2015-10-22 | 2020-05-05 | 天津药物研究院有限公司 | 一种1，2，3-丙三酸偶联的epo拟肽衍生物及其制备方法和应用 |
| ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
| CN106928338A (zh) * | 2015-12-31 | 2017-07-07 | 杭州阿德莱诺泰制药技术有限公司 | 促红细胞生成素肽及衍生物和聚合物、制备方法和应用 |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| US20180092770A1 (en) * | 2016-03-14 | 2018-04-05 | Virchow Biotech Pvt. Ltd. | Sterile protective cover comprising a device for opthalmic delivery |
| US20170258633A1 (en) * | 2016-03-14 | 2017-09-14 | Virchow Biotech Pvt. Ltd. | Novel device for ophthalmic delivery |
| US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| MX2018013616A (es) | 2016-05-13 | 2019-02-21 | Amgen Inc | Montaje de cubierta protectora de vial. |
| EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| GB201609083D0 (en) | 2016-05-24 | 2016-07-06 | Syntab Therapeutics Gmbh | Synthetic compound |
| US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
| US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
| MX2019008432A (es) | 2017-01-17 | 2019-11-18 | Amgen Inc | Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje. |
| MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
| US11752258B2 (en) | 2017-02-17 | 2023-09-12 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
| JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
| US11571511B2 (en) | 2017-03-07 | 2023-02-07 | Amgen Inc. | Insertion mechanism and method of inserting a needle of a drug delivery device |
| MX2019010671A (es) | 2017-03-09 | 2019-10-21 | Amgen Inc | Mecanismo de insercion para dispositivo de administracion de farmacos. |
| EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
| JP7118993B2 (ja) | 2017-03-28 | 2022-08-16 | アムジエン・インコーポレーテツド | プランジャーロッド・シリンジアセンブリシステム及び方法 |
| AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
| AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
| MX2019015479A (es) | 2017-06-23 | 2020-02-20 | Amgen Inc | Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador. |
| JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
| EP3655063A1 (en) | 2017-07-21 | 2020-05-27 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
| MA49677A (fr) | 2017-07-25 | 2021-04-21 | Amgen Inc | Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé |
| MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
| US12318593B2 (en) | 2017-08-09 | 2025-06-03 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
| EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
| MA50614A (fr) | 2017-10-06 | 2020-08-12 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé |
| EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| IL273582B2 (en) | 2017-11-03 | 2024-12-01 | Amgen Inc | Systems and approaches for sterilizing a drug delivery device |
| EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
| MA50553A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Dispositif d'administration de médicament avec détection de positionnement et de débit |
| EP3706826A1 (en) | 2017-11-10 | 2020-09-16 | Amgen Inc. | Plungers for drug delivery devices |
| CA3079540A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
| IL273636B1 (en) | 2017-11-16 | 2025-06-01 | Amgen Inc | Automatic injector with delay and end point sensing |
| US10679942B2 (en) * | 2018-03-15 | 2020-06-09 | International Business Machines Corporation | Electrical junction for facilitating an integration of electrical crossing |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| MA53379A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
| WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
| EP3826699A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
| US12109389B2 (en) | 2018-07-31 | 2024-10-08 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| AU2019347710B2 (en) | 2018-09-24 | 2025-05-08 | Amgen Inc. | Interventional dosing systems and methods |
| AU2019350660B2 (en) | 2018-09-28 | 2024-09-26 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| US12156991B2 (en) | 2018-10-02 | 2024-12-03 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
| WO2020072846A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
| EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
| AU2019359801B2 (en) | 2018-10-15 | 2025-01-02 | Amgen Inc. | Platform assembly process for drug delivery device |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| AU2019370159B2 (en) | 2018-11-01 | 2025-05-29 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
| CN109776359B (zh) * | 2019-03-07 | 2021-03-09 | 暨明医药科技（苏州）有限公司 | 一种Boc-1-氨基-3,6-二氧杂-1,8-辛二胺的合成工艺 |
| EP3958934B1 (en) | 2019-04-24 | 2025-04-09 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
| MX2022002149A (es) | 2019-08-23 | 2022-03-17 | Amgen Inc | Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados. |
| MX2023013640A (es) | 2021-05-21 | 2023-11-30 | Amgen Inc | Metodo de optimizacion de una receta de llenado para un contenedor de medicamento. |
| AU2023374183A1 (en) | 2022-11-02 | 2025-03-20 | F. Hoffmann-La Roche Ag | Method for producing glycoprotein compositions |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4677195A (en) | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5006333A (en) | 1987-08-03 | 1991-04-09 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| DK0400472T3 (da) | 1989-05-27 | 1996-05-13 | Sumitomo Pharma | Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein |
| US5292654A (en) | 1990-12-13 | 1994-03-08 | Whitehead Institute For Biomedical Research | Mutant EPO receptor and uses therefor |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| AU1676992A (en) | 1991-03-18 | 1992-10-21 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
| US5580853A (en) | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
| US5747446A (en) | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
| US5919758A (en) | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5677280A (en) | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
| US5654276A (en) | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
| KR100436680B1 (ko) | 1995-06-07 | 2004-09-18 | 글락소 그룹 리미티드 | 트롬보포이에틴 수용체에 결합하는 펩티드 및 화합물 |
| US5683983A (en) | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
| JP4050314B2 (ja) | 1995-06-07 | 2008-02-20 | オーソ ファーマシューティカル コーポレイション | エリトロポエチン受容体に結合する化合物およびペプチド |
| US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| WO1996040189A1 (en) | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5668110A (en) | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
| US6251864B1 (en) | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6346390B1 (en) | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
| US7091311B2 (en) * | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| US6103879A (en) | 1996-06-21 | 2000-08-15 | Axys Pharmaceuticals, Inc. | Bivalent molecules that form an activating complex with an erythropoietin receptor |
| AU3908597A (en) | 1996-08-02 | 1998-02-25 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
| US5932546A (en) | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
| US6221608B1 (en) | 1997-01-22 | 2001-04-24 | Ortho Pharmaceutical Corporation | Methods for identifying erythropoietin receptor binding protein |
| JPH114133A (ja) * | 1997-06-12 | 1999-01-06 | Murata Mfg Co Ltd | 厚み縦圧電共振子 |
| US6211608B1 (en) | 1998-06-11 | 2001-04-03 | Micron Technology, Inc. | Field emission device with buffer layer and method of making |
| WO2000007629A2 (en) | 1998-08-06 | 2000-02-17 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| DK1588716T3 (da) | 1998-08-06 | 2011-05-23 | Mountain View Pharmaceuticals | Peg-uratoxidase-konjugater og anvendelse deraf |
| EP1008355A1 (en) | 1998-12-08 | 2000-06-14 | Debio Recherche Pharmaceutique S.A. | Method for identifying or analyzing polymer linkage sites on macromolecules using amino acid report binding |
| DE69914611T2 (de) | 1998-08-28 | 2004-12-23 | Gryphon Therapeutics, Inc., South San Francisco | Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DE122009000039I1 (de) | 1998-10-23 | 2009-11-05 | Kirin Amgen Inc | Thrombopoietin substitute |
| DE69929464T2 (de) | 1998-11-17 | 2006-09-07 | Smithkline Beecham Corp. | Zyklische polyamine zur behandlung der thrombozytopenie |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| AUPQ873300A0 (en) | 2000-07-12 | 2000-08-03 | Medvet Science Pty. Ltd. | A binding motif of a receptor (2) |
| AU771460B2 (en) | 1999-09-24 | 2004-03-25 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| EP1221482B1 (en) | 1999-09-27 | 2005-12-28 | Chugai Seiyaku Kabushiki Kaisha | Hemopoietin receptor protein, nr12 |
| US6703480B1 (en) * | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
| US6858630B2 (en) | 1999-12-06 | 2005-02-22 | Smithkline Beecham Corporation | Naphthimidazole derivatives and their use as thrombopoietin mimetics |
| US7109299B1 (en) * | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
| CA2403669A1 (en) | 2000-03-21 | 2001-09-27 | Wisconsin Alumni Research Foundation | Methods and reagents for regulation of cellular responses in biological systems |
| US6777387B2 (en) | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
| RS51292B (sr) | 2000-05-15 | 2010-12-31 | F. Hoffmann-La Roche Ag. | Nova farmaceutska smeša |
| MXPA02011727A (es) * | 2000-05-26 | 2003-10-24 | Johnson & Johnson | Peptidos neuroprotectores. |
| MXPA03001039A (es) | 2000-08-02 | 2004-09-10 | Johnson & Johnson | Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina. |
| AU2001273385B2 (en) | 2000-09-08 | 2005-04-07 | Gryphon Therapeutics, Inc. | Polymer-modified synthetic proteins |
| CA2431964C (en) | 2000-12-20 | 2013-09-10 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| JP2004532289A (ja) | 2001-02-20 | 2004-10-21 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 末端分枝高分子リンカーおよびそれを含む高分子複合体 |
| FR2823220B1 (fr) | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
| US20020169128A1 (en) | 2001-04-09 | 2002-11-14 | Geroge Sigounas | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| AU2002345938A1 (en) | 2001-06-28 | 2003-03-03 | Mountain View Pharmaceuticals, Inc. | Polymer stabilized proteinases |
| US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US20050176627A1 (en) | 2002-09-09 | 2005-08-11 | Anthony Cerami | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| GEP20084486B (en) | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
| KR101162908B1 (ko) | 2002-12-26 | 2012-07-06 | 마운틴 뷰 파마슈티컬즈, 인크. | 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체 |
| CA2525464A1 (en) | 2003-05-12 | 2004-11-25 | Qun Yin | Novel poly(ethylene glycol) modified compounds and uses thereof |
| EA010015B1 (ru) | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов |
| CA2525568C (en) | 2003-05-12 | 2017-07-25 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| BRPI0411172A (pt) | 2003-05-12 | 2006-07-18 | Affymax Inc | peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica |
-
2004
- 2004-05-12 BR BRPI0411172-9A patent/BRPI0411172A/pt not_active IP Right Cessation
- 2004-05-12 EP EP04760995A patent/EP1625156B1/en not_active Expired - Lifetime
- 2004-05-12 NZ NZ543935A patent/NZ543935A/en not_active IP Right Cessation
- 2004-05-12 HR HRP20120989TT patent/HRP20120989T1/hr unknown
- 2004-05-12 KR KR1020127014202A patent/KR20120094001A/ko not_active Ceased
- 2004-05-12 MX MXPA05012313A patent/MXPA05012313A/es active IP Right Grant
- 2004-05-12 PT PT47609953T patent/PT1625156E/pt unknown
- 2004-05-12 US US10/555,868 patent/US7528104B2/en not_active Expired - Fee Related
- 2004-05-12 AU AU2004238868A patent/AU2004238868B2/en not_active Ceased
- 2004-05-12 CN CN2004800199359A patent/CN1823088B/zh not_active Expired - Fee Related
- 2004-05-12 JP JP2006532997A patent/JP4949844B2/ja not_active Expired - Fee Related
- 2004-05-12 EA EA200501798A patent/EA010099B1/ru not_active IP Right Cessation
- 2004-05-12 KR KR1020057021602A patent/KR101227666B1/ko not_active Expired - Fee Related
- 2004-05-12 ES ES04760995T patent/ES2395413T3/es not_active Expired - Lifetime
- 2004-05-12 DK DK04760995.3T patent/DK1625156T3/da active
- 2004-05-12 CA CA002525497A patent/CA2525497A1/en not_active Abandoned
- 2004-05-12 SI SI200431975T patent/SI1625156T1/sl unknown
- 2004-05-12 PL PL04760995T patent/PL1625156T3/pl unknown
- 2004-05-12 WO PCT/US2004/014886 patent/WO2004101611A2/en active Application Filing
-
2005
- 2005-12-02 IS IS8167A patent/IS8167A/is unknown
- 2005-12-08 ZA ZA200509971A patent/ZA200509971B/en unknown
- 2005-12-09 NO NO20055847A patent/NO20055847L/no not_active Application Discontinuation
-
2009
- 2009-03-17 US US12/405,599 patent/US8304391B2/en not_active Expired - Fee Related
- 2009-05-20 IL IL198844A patent/IL198844A0/en unknown
-
2012
- 2012-10-18 US US13/654,507 patent/US20130130979A1/en not_active Abandoned
- 2012-11-01 US US13/666,579 patent/US20130244939A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120989T1 (hr) | Peptidi koji se vežu za receptor eritropoetina | |
| Deng et al. | Functional polypeptide and hybrid materials: Precision synthesis via α-amino acid N-carboxyanhydride polymerization and emerging biomedical applications | |
| Chassenieux et al. | Recent trends in pH/thermo-responsive self-assembling hydrogels: from polyions to peptide-based polymeric gelators | |
| CN103087311B (zh) | 两亲性三嵌段聚合物及其制备方法和应用 | |
| BG104570A (en) | Erythropoetin conjugates | |
| Otter et al. | Supramolecular assembly of functional peptide–polymer conjugates | |
| Luo et al. | Thermoresponsive self‐assembly of nanostructures from a collagen‐like peptide‐containing diblock copolymer | |
| Krannig et al. | Emerging bioinspired polymers: glycopolypeptides | |
| JP2008542399A5 (hr) | ||
| JP2007526330A5 (hr) | ||
| WO1998052614A3 (en) | Composition and method for enhancing transport across biological membranes | |
| Klok et al. | Dendritic− graft polypeptides | |
| EP2625191A1 (en) | A thermo-responsive polymer covalently bound with a peptide | |
| WO2006090924A1 (ja) | ペプチドリガンドを有するブロック共重合体 | |
| CA2355705A1 (fr) | Polyetheresteramides et compositions de polymeres antistatiques les contenant | |
| Bauer et al. | Secondary structure-driven self-assembly of thiol-reactive polypept (o) ides | |
| JP2010520855A5 (hr) | ||
| Nieto-Orellana et al. | Effect of polymer topology on non-covalent polymer–protein complexation: Miktoarm versus linear mPEG-poly (glutamic acid) copolymers | |
| US20120271003A1 (en) | Block Copolymers As Thermoplastic Elastomers Made Of Polyisobutene Blocks And Oligoamide Blocks | |
| Huang et al. | Polypeptide–poly (ethylene glycol) miktoarm star copolymers with a fluorescently labeled core: Synthesis, delivery and imaging of siRNA | |
| Ma et al. | Development of polypeptide-based zwitterionic amphiphilic micelles for nanodrug delivery | |
| CN107556497A (zh) | 一种杂化水凝胶材料的制备方法及应用 | |
| JP2007504169A5 (hr) | ||
| Cai et al. | Guanidinated multi-arm star polyornithines with a polyethylenimine core for gene delivery | |
| JP2008519858A5 (hr) |